The future of pharmacogenetics in Parkinson's disease treatment

Pharmacogenomics. 2018 Feb;19(3):171-174. doi: 10.2217/pgs-2017-0180. Epub 2017 Dec 1.

Authors

Mara H Hutz¹, Carlos Rm Rieder²

Affiliations

¹ Departamento de Genética, Instituto de Biociências, Universidade Federal do Rio Grande do Sul, Porto Alegre, 91501-970, Brazil.
² Serviço de Neurologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, 90035-903, Brazil.

PMID: 29191064
DOI: 10.2217/pgs-2017-0180

No abstract available

Keywords: Parkinson's disease; genetic diversity; pharmacogenomics.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Antiparkinson Agents / adverse effects
Antiparkinson Agents / pharmacokinetics
Antiparkinson Agents / therapeutic use*
Humans
Levodopa / adverse effects
Levodopa / pharmacokinetics
Levodopa / therapeutic use*
Motor Activity / drug effects
Motor Activity / genetics
Parkinson Disease / drug therapy*
Parkinson Disease / genetics*
Pharmacogenetics*
Receptors, Dopamine / genetics

Substances

Antiparkinson Agents
Receptors, Dopamine
Levodopa